TY - JOUR
T1 - Molecular monitoring 101
T2 - Helping your patients with chronic myeloid leukemia to understand the meaning of molecular response
AU - Jabbour, Elias J.
AU - Quintás-Cardama, Alfonso
PY - 2012/8
Y1 - 2012/8
N2 - For patients with chronic myeloid leukemia (CML), measurement of molecular response (i.e. the level of BCR-ABL1 transcripts) is firmly established as a key element of disease monitoring. Assessment of BCR-ABL1 levels may help to identify early signs of resistance to treatment and enable a timely switch to alternative therapies. Hence, regular and accurate monitoring of BCR-ABL1 transcripts helps to maximize the chance of successful outcomes in CML. Because the incidence of CML is relatively low, many community oncologists encounter only a limited number of cases; measuring and interpreting BCR-ABL1 measurements in a clinically relevant fashion may be challenging. The team at our institution often encounters questions regarding real-time quantitative polymerase chain reaction assessments of BCR-ABL1 levels, International Scale standardization, the implications of achieving or losing molecular responses and mutation monitoring. The aim of this article is to provide practical advice for effective long-term monitoring of patients with CML by addressing frequently asked questions and common case scenarios using guideline- and evidence-based approaches.
AB - For patients with chronic myeloid leukemia (CML), measurement of molecular response (i.e. the level of BCR-ABL1 transcripts) is firmly established as a key element of disease monitoring. Assessment of BCR-ABL1 levels may help to identify early signs of resistance to treatment and enable a timely switch to alternative therapies. Hence, regular and accurate monitoring of BCR-ABL1 transcripts helps to maximize the chance of successful outcomes in CML. Because the incidence of CML is relatively low, many community oncologists encounter only a limited number of cases; measuring and interpreting BCR-ABL1 measurements in a clinically relevant fashion may be challenging. The team at our institution often encounters questions regarding real-time quantitative polymerase chain reaction assessments of BCR-ABL1 levels, International Scale standardization, the implications of achieving or losing molecular responses and mutation monitoring. The aim of this article is to provide practical advice for effective long-term monitoring of patients with CML by addressing frequently asked questions and common case scenarios using guideline- and evidence-based approaches.
KW - BCR- ABL1
KW - Chronic myeloid leukemia
KW - tyrosine kinase inhibitor therapy
UR - http://www.scopus.com/inward/record.url?scp=84864253100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864253100&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.659734
DO - 10.3109/10428194.2012.659734
M3 - Review article
C2 - 22273251
AN - SCOPUS:84864253100
SN - 1042-8194
VL - 53
SP - 1452
EP - 1460
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -